FEW FACTS ABOUT VIJYOTI FOUNDER
Mr Vijay G Pande has over five decades of experience in
development of educational institutions, R&D protocols and
regimes focused on societal benefits, and related capacity
development in South Asia and South East Asia. He is an alumnus
of the London School of Economics, University of London. During his
over sixteen years with the Ford Foundation, and subsequent
fourteen years with the International Development Research Center
(IDRC), Canada, he was intimately associated with Population
Foundation of India, National Institute of Immunology, IIMAhmedabad, IIT-Kanpur and lot many other institutes in India and
abroad. He is a founder member of the London School of Economics
Society, New Delhi.
What drives the need?
• 1.2 billion people in India need 12 million units of blood
annually but there is collection of only 9 million - a 25 percent
deficit.
• Growing awareness about evidence-based and not the current
behavior based blood transfusion.
ROTEM-based diagnostics related to
excessive bleeding is targeted and
evidence-based that helps doctors in
judicious use of blood transfusion and
use of blood products thereby
minimizing use of blood transfusion.
This in turn minimizes risks of
mortality, morbidity, hospital-acquired
infection – sepsis – arising from RBC
transfusion. It also leads to reduction
in costs to patient, hospitals, and other
stakeholders like medical insurance
companies and blood banks.
As per Mr Vijay G Pande, Managing
Director of Vijyoti Management And
Communications Learning Institute
and Founder – President of Vijyoti
Education Foundation, “Vijyoti’s
experience in the health sector,
where it has worked with noted
companies/institutions like Daiichi and
Ranbaxy, and my own experience in
institution building and capacity
development in the health sector, for
example, the Population Foundation,
and National Institute of Immunology
through my former association with the
International Development Research
Centre, Canada, and the Ford
Foundation make us a natural partner
of Tem International.”
On the question of the nature of
partnership with TEM, Mr Pande says,
“Leveraging its expertise in human
resources and marketing
communication for capacity
development and change, Vijyoti
partners with select companies who
offer innovative solutions for mass
benefit, from start-ups to Fortune 500
companies, family-owned to
multinationals, across the globe. Our
partnership with TEM too is both for
marketing and after sales, and –
equally important – for educating and
creating awareness on PBM through a
program of continuing education in
this area.”
Economic viability of ROTEM
As per the management of Vijyoti, the
device is in the median price range of
medical devices in India and the
benefits of the technology allows for
immense benefits that give a return on
investment within 3 to 6 months, as
seen in US, Canada and Europe,
depending upon utilization.
Applying the concept of PBM, the
devices help hospitals save millions of
dollars annually on blood products,
optimizes patient healthcare and most
importantly, ensures efficient use of
blood, a scarce resource, avoiding
wastage and promoting blood
conservation.
As per Mr Pande, the market potential
for ROTEM is within the realm of
economic viability. “Our immediate
plans for ROTEM’s adoption are
focused on educating all stakeholders
on the concept and fundamentals of
Patient Bleeding Management System
through a programme of Continuing
Medical Education, he mentioned while
elaborating further, “If we consider a
simple scenario where one unit of
blood costs around Rs 1500, the
probable market size of blood in India
(1500 x12) would be Rs 18000 million
(Rs 18 billion/1800 crores) market.
Blood and blood components have
generated billions of dollars in revenue
for entities that deal in non-profit
blood supply even though profiteering
is not one of the things associated with
blood banking.”
BIOVOICENEWS.COM
37